CoChat

EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration

Open access
Tano, Yasuo, Ohji, Masahito · 2010 · Acta Ophthalmologica
Cited by 50

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

: Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) secondary to age‐related macular degeneration (AMD) in Japanese patients. Methods: This open‐label, multicentre, Phase I/II study enroled patients into Group A (single injection of ranibizumab nonrandomized doses of 0.3 or 0.5 mg followed by 11 monthly injections of the same dose) and Group B (12 monthly injections of ranibizumab randomized to 0.3 or 0.5 mg). The primary efficacy endpoint was the mean change from baseline in best‐corrected visual acuity (BCVA) score at Month 6. Safety was evaluated in all patients who received ranibizumab. Results: Of 88 patients enroled, 12 entered Group A (six per dose) and 76 entered Group B (0.3 mg: n = 35; 0.5 mg: n = 41). Mean change from baseline in BCVA was significantly increased for both doses (Group B) at Month 6 (0.3 mg: +8.1 letters, p = 0.0006; 0.5 mg: +9.0 letters, p < 0.0001) and Month 12 (0.3 mg: +9.5 letters, p = 0.0001; 0.5 mg: +10.5 letters, p < 0.0001). At Month 12, one patient (0.3 mg) and 0 patients (0.5 mg) lost ≥15 letters, while 37.1% (0.3 mg) and 31.7% (0.5 mg) of patients gained ≥15 letters. Ocular serious adverse events (SAEs) of the study eye were reported in 1 and 2 patients in the 0.3‐ and 0.5‐mg groups, respectively. Nonocular SAEs were experienced by 2 and 5 patients in the 0.3‐ and 0.5‐mg groups, respectively. No cases of endophthalmitis were reported. Conclusion: Ranibizumab was effective and well tolerated in Japanese patients with subfoveal CNV secondary to AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-3768.2009.01843.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

    Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 4×

    “In addition, the incidences of nonocular AEs suspected to be related to ranibizumab and AEs potentially related to systemic VEGF inhibition were also within the acceptable range and consistent with the earlier studies (Brown et al. 2006; Rosenfeld et al. 2006).”
    BackgroundResultInfluential
  • Prevalence and Risk Factors for Age-Related Macular Degeneration in an Adult Japanese Population

    Kawasaki, R., Wang, J. J., Ji, G.-J., Taylor, B., Oizumi, T., Daimon, M., Kato, T., Kawata, S., Kayama, T., Tano, Y., et al. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.11.015 · Cited by 138 · cited 1×

    “However, another recent study (the Funagata study) of Japanese residents aged 35 years or older (n = 1758) between 2000 and 2002 suggested that although the prevalence of neovascular AMD was lower in Japanese women, it was similar to that seen in Caucasians for Japanese men (Kawasaki et al. 2008).”
    ResultSelf-citation

Show all 2 references

Cited by

See all 50

Metadata

Authors
Tano, Y., & Ohji, M.
Venue
Acta Ophthalmologica
Publisher
Wiley
Published
2010-04-27
Volume
88
Issue
3
Pages
309-316
ISSN
  • 0001-639X (ISSN-L)
  • 1755-375X
  • 1755-3768
OpenAlex
W1976685144
Cited by
50
References
2
FWCI
5.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration. https://app.cochat.ai/papers/10.1111/j.1755-3768.2009.01843.x
The paper
Tano, Y., & Ohji, M. (2010). EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration. Acta Ophthalmologica. https://doi.org/10.1111/j.1755-3768.2009.01843.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.